I

n a surprise move, U.S. regulators approved a generic version of Teva Pharmaceutical’s (TEVA) Copaxone multiple sclerosis drug earlier than investors expected. And the decision portends big changes not only for Teva — Copaxone is a key contributor to its sales and profits — but also for generic companies more broadly, as far as some Wall Street wags are concerned.

The approval creates a heightened challenge for Teva, which is already in disarray. Two months ago, the drug maker — which is the world’s biggest purveyor of generics — missed earnings estimates, lowered its profit guidance for the year, cut its dividend by 75 percent, and disclosed plans to axe another 1,000 jobs and close 15 manufacturing plants.  Then there’s its $35 billion debt load.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy